Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Dezember 2025 08:30 ET | Quelle: Bioheng Therapeutics

Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy

BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced the successful dosing of...
08. Dezember 2025 18:00 ET | Quelle: Bioheng Therapeutics

Imviva Biotech Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemias Findings underscore potential to address unmet needs in multiple...
08. Dezember 2025 17:15 ET | Quelle: Bioheng Therapeutics

Imviva Biotech Presents Clinical Breakthroughs for CTD402 in High-Mortality T-Cell and Myeloid Leukemias at the 67th American Society of Hematology Annual Meeting

BOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402,...
24. November 2025 08:30 ET | Quelle: Bioheng Therapeutics

Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting

Two oral, and five poster presentations will showcase the company’s progress in developing allogenic cell therapy candidates for multiple hematological malignancies CTD402 data for the treatment of...